| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
|
Ou D.-L.; Lee B.-S.; Chang Y.-C.; Lin L.-I.; Liou J.-Y.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:08Z |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin
|
Ou D.-L.;Lee B.-S.;Lin L.-I.;Liou J.-Y.;Liao S.-C.;Chiun Hsu;Cheng A.-L.; Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou D.-L.;Shyue S.-K.;Lin L.-I.;Feng Z.-R.;Liou J.-Y.;Fan H.-H.;Lee B.-S.;Chiun Hsu;Cheng A.-L.Ann-Lii; Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Chiun Hsu; Cheng A.-L.Ann-Lii |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
H3K9 histone methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis
|
Wu P.-C.; Lu J.-W.; Yang J.-Y.; Lin I.-H.; Ou D.-L.; Lin Y.-H.; Chou K.-H.; Huang W.-F.; Wang W.-P.; Huang Y.-L.; Chiun Hsu; Lin L.-I.; Lin Y.-M.; James Shen C.-K.; Tzeng T.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Chiun Hsu; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; YU-YUN SHAO; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-03-30T03:55:55Z |
Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases
|
Lin L.-I.; Lin K.-S.; Chang J.-S.; Lin D.-T.; Lin Tsai S.-J.; SHYH-CHYI LO; Pai S.-C.; Pai S.-C.;Shyh-Chyi Lo;Lin Tsai S.-J.;Chang J.-S.;Lin D.-T.;Lin K.-S.;Lin L.-I. |
| 臺大學術典藏 |
2020-03-07T06:56:33Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S. |
| 臺大學術典藏 |
2020-03-07T06:56:33Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-07T06:56:25Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L.; Tseng L.-H.; Lin L.-I.; Hung J.-S.; Lin B.-R.; Liau J.-Y.; Liang J.-T.; Tsai J.-H.; Liang Y.-H.; Lin Y.-.; Lin Y.-.;Liang Y.-H.;Tsai J.-H.;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Yih-Leong Chang;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-03-07T06:56:23Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Yih-Leong Chang;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:18Z |
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L.; Chen K.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Tseng L.-H.;Lin L.-I.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Yih-Leong Chang;Yeh K.-H.;Cheng A.-L.; Chen K.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H. |
| 臺大學術典藏 |
2020-03-07T06:42:09Z |
Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression
|
Huang H.-N.;Lin M.-C.;Tseng L.-H.;Chiang Y.-C.;Lin L.-I.;Lin Y.-F.;Huang H.-Y.;Kuan-Ting Kuo; Huang H.-Y.; KUAN-TING KUO; Lin L.-I.; Lin Y.-F.; Chiang Y.-C.; Tseng L.-H.; Lin M.-C.; Huang H.-N. |
| 臺大學術典藏 |
2020-03-06T08:25:04Z |
Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis
|
Cheng Y.-C.; Cheng M.-L.; YUNG-MING JENG; Tsai J.-H.; Liau J.-Y.; Lin Y.-L.; Lin L.-I. |
| 臺大學術典藏 |
2020-03-06T08:25:01Z |
Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma
|
Tsai J.-H.;Lin Y.-L.;Cheng Y.-C.;Chen C.-C.;Lin L.-I.;Tseng L.-H.;Cheng M.-L.;Liau J.-Y.;Yung-Ming Jeng; Tsai J.-H.; Lin Y.-L.; Cheng Y.-C.; Chen C.-C.; Lin L.-I.; Tseng L.-H.; Cheng M.-L.; Liau J.-Y.; YUNG-MING JENG |
| 臺大學術典藏 |
2020-03-06T08:24:55Z |
Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: Association with distinct clinicopathological and molecular features and poor clinical outcome
|
Tsai J.-H.;Liau J.-Y.;Lin Y.-L.;Tseng L.-H.;Lin L.-I.;Yeh K.-H.;Yung-Ming Jeng; Tsai J.-H.; Liau J.-Y.; Lin Y.-L.; Tseng L.-H.; Lin L.-I.; Yeh K.-H.; YUNG-MING JENG |
| 臺大學術典藏 |
2020-03-06T05:26:20Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-06T05:26:15Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-06T05:26:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:09Z |
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
Chen K.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T12:22:25Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; SHAN-CHI YU; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T12:22:25Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Liau J.-Y.; SHAN-CHI YU; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.; Lin Y.-L. |
| 臺大學術典藏 |
2020-03-05T07:52:33Z |
Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression
|
Huang H.-N.; Lin M.-C.; Tseng L.-H.; Chiang Y.-C.; Lin L.-I.; Lin Y.-F.; Huang H.-Y.; KUAN-TING KUO |
| 臺大學術典藏 |
2020-03-05T07:31:48Z |
Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis
|
JIA-HUEI TSAI; Liau J.-Y.; Lin Y.-L.; Lin L.-I.; Cheng Y.-C.; Cheng M.-L.; Jeng Y.-M. |
| 臺大學術典藏 |
2020-03-05T07:31:48Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.;Liang Y.-H.;Jia-Huei Tsai;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Chang Y.-L.;Yeh K.-H.;Cheng A.-L.; Lin Y.-.; Liang Y.-H.; JIA-HUEI TSAI; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T07:31:46Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Jia-Huei Tsai;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Yeh K.-H.; Cheng A.-L.; Chang Y.-L.; Lin L.-I.; Tseng L.-H.; JIA-HUEI TSAI; Liang J.-T.; Lin B.-R.; Hung J.-S. |
| 臺大學術典藏 |
2020-03-05T07:31:45Z |
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
Chen K.-H.; Lin Y.-L.; Liau J.-Y.; JIA-HUEI TSAI; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T07:31:45Z |
Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: Association with distinct clinicopathological and molecular features and poor clinical outcome
|
Jia-Huei Tsai;Liau J.-Y.;Lin Y.-L.;Tseng L.-H.;Lin L.-I.;Yeh K.-H.;Jeng Y.-M.; JIA-HUEI TSAI; Liau J.-Y.; Lin Y.-L.; Tseng L.-H.; Lin L.-I.; Yeh K.-H.; Jeng Y.-M. |
| 臺大學術典藏 |
2020-03-05T07:31:44Z |
Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF-mutated serrated lesions
|
JIA-HUEI TSAI; Cheng C.-H.; Chen C.-C.; Lin Y.-L.; Lin L.-I.; Chen M.-L.; Liau J.-Y. |
| 臺大學術典藏 |
2020-03-05T06:28:43Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Cheng A.-L.; Yeh K.-H.; Chang Y.-L.; Hung J.-S.; Lin Y.-L.; JAU-YU LIAU; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R. |
| 臺大學術典藏 |
2020-03-05T06:28:40Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Cheng A.-L.; Chang Y.-L.; Yeh K.-H.; Tseng L.-H.; Lin L.-I.; Hung J.-S.; Lin B.-R.; Liang J.-T.; Lin Y.-.; Liang Y.-H.; Tsai J.-H.; JAU-YU LIAU |
| 臺大學術典藏 |
2020-03-05T06:28:39Z |
Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis
|
Tsai J.-H.;Jau-Yu Liau;Lin Y.-L.;Lin L.-I.;Cheng Y.-C.;Cheng M.-L.;Jeng Y.-M.; Tsai J.-H.; JAU-YU LIAU; Lin Y.-L.; Lin L.-I.; Cheng Y.-C.; Cheng M.-L.; Jeng Y.-M. |
| 臺大學術典藏 |
2020-03-05T06:28:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Jau-Yu Liau;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; JAU-YU LIAU; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-05T06:28:37Z |
Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma
|
Tsai J.-H.;Lin Y.-L.;Cheng Y.-C.;Chen C.-C.;Lin L.-I.;Tseng L.-H.;Cheng M.-L.;Jau-Yu Liau;Jeng Y.-M.; Tsai J.-H.; Lin Y.-L.; Cheng Y.-C.; Chen C.-C.; Lin L.-I.; Tseng L.-H.; Cheng M.-L.; JAU-YU LIAU; Jeng Y.-M. |
| 臺大學術典藏 |
2020-03-05T06:28:33Z |
Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF-mutated serrated lesions
|
Tsai J.-H.;Cheng C.-H.;Chen C.-C.;Lin Y.-L.;Lin L.-I.;Chen M.-L.;Jau-Yu Liau; Tsai J.-H.; Cheng C.-H.; Chen C.-C.; Lin Y.-L.; Lin L.-I.; Chen M.-L.; JAU-YU LIAU |
| 臺大學術典藏 |
2020-03-05T06:28:33Z |
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
Chen K.-H.;Lin Y.-L.;Jau-Yu Liau;Tsai J.-H.;Tseng L.-H.;Lin L.-I.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Chang Y.-L.;Yeh K.-H.;Cheng A.-L.; Chen K.-H.; Lin Y.-L.; JAU-YU LIAU; Tsai J.-H.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T06:28:33Z |
Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: Association with distinct clinicopathological and molecular features and poor clinical outcome
|
Tsai J.-H.; JAU-YU LIAU; Lin Y.-L.; Tseng L.-H.; Lin L.-I.; Yeh K.-H.; Jeng Y.-M. |
| 臺大學術典藏 |
2020-03-05T06:28:28Z |
CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer
|
Chen K.-H.;Lin L.-I.;Tseng L.-H.;Lin Y.-L.;Jau-Yu Liau;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Cheng A.-L.;Yeh K.-H.; Chen K.-H.; Lin L.-I.; Tseng L.-H.; Lin Y.-L.; JAU-YU LIAU; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-02-25T05:15:28Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-02-25T05:15:26Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Liau J.-Y.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.; Lin Y.-.; Liang Y.-H.; Tsai J.-H. |
| 臺大學術典藏 |
2020-02-25T05:15:25Z |
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
Chen K.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-02-25T05:15:25Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-02-24T02:29:11Z |
CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer
|
Lin L.-I.; Tseng L.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; BEEN-REN LIN; Cheng A.-L.; Yeh K.-H.; Chen K.-H.; Chen K.-H.;Lin L.-I.;Tseng L.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Been-Ren Lin;Cheng A.-L.;Yeh K.-H. |
| 臺大學術典藏 |
2020-02-14T08:50:33Z |
Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression
|
Huang H.-N; Lin M.-C; Tseng L.-H; YING-CHENG CHIANG; Lin L.-I; Lin Y.-F; Huang H.-Y; Kuo K.-T. |
| 臺大學術典藏 |
2019-12-24T09:05:42Z |
Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
|
Tsai C.-H.;Yao C.-Y.;Tien F.-M.;Tang J.-L.;Kuo Y.-Y.;Chiu Y.-C.;Lin C.-C.;Tseng M.-H.;Peng Y.-L.;Liu M.-C.;Liu C.-W.;Yao M.;Lin L.-I.;Chou W.-C.;Chen C.-Y.;Hou H.-A.;Tien H.-F.; Tsai C.-H.; Yao C.-Y.; Tien F.-M.; Tang J.-L.; Kuo Y.-Y.; Chiu Y.-C.; Lin C.-C.; Tseng M.-H.; Peng Y.-L.; Liu M.-C.; Liu C.-W.; Yao M.; Lin L.-I.; Chou W.-C.; Chen C.-Y.; Hou H.-A.; Tien H.-F.; CHIEN-YU CHEN |
| 臺大學術典藏 |
2019 |
CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer
|
Liau J.-Y.; JIA-HUEI TSAI; Liang J.-T.; Lin B.-R.; Cheng A.-L.; Yeh K.-H.; Lin Y.-L.; Tseng L.-H.; Lin L.-I.; Chen K.-H.; Chen K.-H.;Lin L.-I.;Tseng L.-H.;Lin Y.-L.;Liau J.-Y.;Jia-Huei Tsai;Liang J.-T.;Lin B.-R.;Cheng A.-L.;Yeh K.-H. |
| 臺大學術典藏 |
2019 |
Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
|
Tien, H.-F.; Hou, H.-A.; Chen, C.-Y.; Lin, C.-C.; Tseng, M.-H.; Peng, Y.-L.; Liu, M.-C.; Liu, C.-W.; Yao, M.; Lin, L.-I.; Chou, W.-C.; Chiu, Y.-C.; Kuo, Y.-Y.; Tang, J.-L.; Tien, F.-M.; Yao, C.-Y.; Tsai, C.-H. |
| 臺大學術典藏 |
2019 |
Cytarabine-resistant FLT3-ITD leukemia cells are associated with TP53 mutation and multiple pathway alterations—possible therapeutic efficacy of cabozantinib
|
Ko Y.-C.; Hu C.-Y.; Liu Z.-H.; HWEI-FANG TIEN; Ou D.-L.; Chien H.-F.; Lin L.-I. |
| 臺大學術典藏 |
2018-09-10T18:07:26Z |
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
|
Hou, H.-A.;Tsai, C.-H.;Lin, C.-C.;Chou, W.-C.;Kuo, Y.-Y.;Liu, C.-Y.;Tseng, M.-H.;Peng, Y.-L.;Liu, M.-C.;Liu, C.-W.;Liao, X.-W.;Lin, L.-I.;Yao, M.;Tang, J.-L.;Tien, H.-F.; WEN-CHIEN CHOU; YUAN-YEH KUO; LIANG-IN LIN; CHIEN-CHIN LIN |
| 臺大學術典藏 |
2018-09-10T15:33:22Z |
Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: Association with distinct clinicopathological and molecular features and poor clinical outcome
|
Tsai, J.-H.;Liau, J.-Y.;Lin, Y.-L.;Tseng, L.-H.;Lin, L.-I.;Yeh, K.-H.;Jeng, Y.-M.; Tsai, Jia-Huei; Lan, C; Lan, C; YUNG-MING JENG; JAU-YU LIAU; Chen, SY; Liau, Jau-Yu; Lin, Yu-Lin; Lai, JS; LIANG-IN LIN; Tseng, Li-Hui; Lin, Liang-In; Yeh, Kun-Huei; Jeng, Yung-Ming |
